Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | VRTX Vertex Pharmaceuticals | ABT Abbott Laboratories |
|---|---|---|
| Price | $513.26 -1.2% | $102.36 -0.7% |
| StockIQ Score | 61C+ Moderate Risk: Medium | 51C- Moderate Risk: Medium |
| Technical | 50C- | 23F |
| Fundamental | 79B+ | 72B |
| Growth | 76B+ | 45D+ |
| Fair Value | 38F | 38F |
| News | 92A+ | 92A+ |
| Quality | 42D | 63C+ |
| Risk | 48D+ | 54C- |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Vertex Pharmaceuticals (VRTX) outperforms Abbott Laboratories (ABT) in growth and fundamentals, with scores of 76 and 79 versus 45 and 72. VRTX also has a higher technical score (70 vs. 50) and investor score (67 vs. 56). However, ABT has a slightly better valuation score (38 vs. 33). Both share a "MODERATE" rating.